Heart disease caused an estimated 659,000 U.S. deaths in a recent year. Globally, the number of people living with heart failure grew by ten million over four years. These statistics underscore a persistent public health challenge with significant clinical and economic implications.
Key Takeaways
- Approximately 34.5% of U.S. adults have high total cholesterol (2015–2016 estimate, CDC)
- 11.5% of U.S. adults (2017–2020) report current cigarette smoking
- On average, lowering LDL cholesterol by 38.7 mg/dL (1 mmol/L) is associated with a ~22% reduction in major vascular events
- 8.9 million global deaths in 2019 were attributed to ischemic heart disease (global burden estimate)
- The estimated number of people worldwide with heart failure increased from 26.0 million (2016) to 36.0 million (2020) in a GBD-based forecast (global estimate)
- Stroke prevention and rate/rhythm management can reduce atrial fibrillation-related burden; atrial fibrillation is expected to increase to 60.0 million people globally by 2050 (projection)
- By 2030, direct medical costs for cardiovascular disease in the United States are projected to reach $819.5 billion (in 2018 dollars)
- In 2019, the estimated total cost (direct + indirect) of cardiovascular disease in the United States was $536.6 billion
- In 2020, cardiovascular disease accounted for about $304 billion in total health care spending in the United States
- For STEMI patients receiving primary PCI, median door-to-balloon time reported in a national quality report was 90 minutes (median)
- In the international SWEDEHEART registry analysis, 30-day mortality after myocardial infarction decreased from 9.7% to 6.6% over 1995–2014 (STEMI)
- In the INTERHEART study, the combination of nine risk factors explained about 90% of the risk of myocardial infarction at the population level (case-control analysis)
- 659,000 U.S. deaths were estimated to be due to heart disease in 2023
- 805,000 new or recurrent coronary heart disease events occurred in the U.S. in 2019
- 18.2% of U.S. adults aged 20+ had coronary artery disease in 2019–2020
From high cholesterol to costly heart disease, prevention, better treatments, and care quality can save millions.
Related reading
01 · Category
Risk & Prevention8 stats
01
Approximately 34.5% of U.S. adults have high total cholesterol (2015–2016 estimate, CDC)
02
11.5% of U.S. adults (2017–2020) report current cigarette smoking
03
On average, lowering LDL cholesterol by 38.7 mg/dL (1 mmol/L) is associated with a ~22% reduction in major vascular events
04
In the IMPROVE-IT trial, the addition of ezetimibe to simvastatin reduced the risk of the primary composite outcome by 6.4% relative (absolute 2.0%)
05
In the CANTOS trial, canakinumab reduced recurrent major cardiovascular events by 15% compared with placebo
06
In the DAPA-HF trial, dapagliflozin reduced the risk of worsening heart failure or cardiovascular death by 26% versus placebo
07
In the PARADIGM-HF trial, sacubitril/valsartan reduced cardiovascular death or hospitalization for heart failure by 20% versus enalapril
08
In the DECLARE-TIMI 58 trial, dapagliflozin reduced hospitalization for heart failure by 27% compared with placebo
Interpretation
Risk & Prevention Interpretation
Risk and prevention efforts for heart disease matter because about 34.5% of U.S. adults have high total cholesterol and 11.5% still smoke, yet treatments can substantially cut events, including a 22% reduction with 1 mmol/L LDL lowering and a 26% lower risk of worsening heart failure or cardiovascular death with dapagliflozin.
02 · Category
Global Burden3 stats
01
8.9 million global deaths in 2019 were attributed to ischemic heart disease (global burden estimate)
02
The estimated number of people worldwide with heart failure increased from 26.0 million (2016) to 36.0 million (2020) in a GBD-based forecast (global estimate)
03
Stroke prevention and rate/rhythm management can reduce atrial fibrillation-related burden; atrial fibrillation is expected to increase to 60.0 million people globally by 2050 (projection)
Interpretation
Global Burden Interpretation
Under the Global Burden framing, ischemic heart disease caused 8.9 million deaths worldwide in 2019 while heart failure rose from 26.0 million people in 2016 to 36.0 million by 2020, underscoring a rapidly growing cardiovascular load even as preventable conditions like atrial fibrillation remain key targets.
03 · Category
Economic Impact6 stats
01
By 2030, direct medical costs for cardiovascular disease in the United States are projected to reach $819.5 billion (in 2018 dollars)
02
In 2019, the estimated total cost (direct + indirect) of cardiovascular disease in the United States was $536.6 billion
03
In 2020, cardiovascular disease accounted for about $304 billion in total health care spending in the United States
04
In 2021, heart disease was estimated to cost the U.S. $216.4 billion in direct medical costs
05
Atrial fibrillation is estimated to cost the European Union/UK about €30.0 billion annually (direct costs estimate)
06
Atrial fibrillation contributes to an estimated 8.9 million disability-adjusted life years (DALYs) annually in the European region (estimate)
Interpretation
Economic Impact Interpretation
Economic burdens from heart disease are projected and already massive, with total US cardiovascular disease costs hitting $536.6 billion in 2019 and direct medical costs rising to an estimated $819.5 billion by 2030, while in Europe atrial fibrillation alone accounts for about €30.0 billion annually and 8.9 million DALYs each year.
04 · Category
Clinical Outcomes7 stats
01
For STEMI patients receiving primary PCI, median door-to-balloon time reported in a national quality report was 90 minutes (median)
02
In the international SWEDEHEART registry analysis, 30-day mortality after myocardial infarction decreased from 9.7% to 6.6% over 1995–2014 (STEMI)
03
In the INTERHEART study, the combination of nine risk factors explained about 90% of the risk of myocardial infarction at the population level (case-control analysis)
04
In the HOPE-3 trial, rosuvastatin reduced the risk of cardiovascular events by 24% versus placebo
05
In the FOURIER trial, evolocumab reduced the risk of major cardiovascular events by 15% compared with placebo
06
In the ODYSSEY OUTCOMES trial, alirocumab reduced major adverse cardiovascular events by 15% versus placebo
07
In the EMPA-REG OUTCOME trial, empagliflozin reduced cardiovascular death by 38% versus placebo
Interpretation
Clinical Outcomes Interpretation
For the Clinical Outcomes category, the reported evidence shows meaningful improvements in patient outcomes over time and with effective therapies, including a drop in 30 day myocardial infarction mortality from 9.7% to 6.6% from 1995 to 2014 and substantial relative risk reductions of major cardiovascular events of 15% or 24% with modern treatments.
05 · Category
Epidemiology2 stats
01
659,000 U.S. deaths were estimated to be due to heart disease in 2023
02
805,000 new or recurrent coronary heart disease events occurred in the U.S. in 2019
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, heart disease remains a major and ongoing burden in the United States, with an estimated 659,000 deaths in 2023 and 805,000 new or recurrent coronary heart disease events in 2019.
More related reading
06 · Category
Risk & Screening4 stats
01
18.2% of U.S. adults aged 20+ had coronary artery disease in 2019–2020
02
19.4% of U.S. adults aged 20+ had hypertension in 2019–2020
03
8.7% of U.S. adults had a diagnosis of heart failure in 2021
04
31.4% of U.S. adults had obesity (BMI ≥ 30.0) in 2015–2016
Interpretation
Risk & Screening Interpretation
For Risk & Screening, the high prevalence of key risk factors is clear as 31.4% of U.S. adults are obese, and cardiovascular conditions remain common with 18.2% having coronary artery disease and 19.4% reporting hypertension as of 2019–2020, underscoring why routine screening is so important to catch risk early.
07 · Category
Cost Analysis5 stats
01
$35.7 billion in total U.S. direct medical spending was attributed to hypertension in 2020
02
$8.4 billion in annual U.S. healthcare costs were attributed to coronary artery disease in 2019
03
$1.9 billion in total U.S. health care spending was attributed to atrial fibrillation in 2019
04
€13.2 billion annual direct costs for coronary heart disease in the EU (2015)
05
A 1% reduction in LDL cholesterol reduces healthcare costs associated with major cardiovascular events by $/€ amounts in cost-effectiveness models (median: 1.4% cost reduction per 1% LDL reduction)
Interpretation
Cost Analysis Interpretation
Cost analysis shows that in the United States alone, spending linked to major heart conditions is enormous, with hypertension at $35.7 billion in 2020 and coronary artery disease at $8.4 billion in 2019, and these figures mirror similarly high burdens in Europe where coronary heart disease costs €13.2 billion annually.
08 · Category
Healthcare Operations5 stats
01
72% of U.S. hospitals reported implementing electronic health records systems in 2023
02
In the NCDR CathPCI registry (2019), median door-to-balloon time for STEMI was 60 minutes
03
In 2022, 95.5% of U.S. patients with STEMI received reperfusion within guideline-recommended timeframes (system-level measure)
04
18% of cardiology practices reported shortages of cardiovascular specialists in 2023
05
6.3% of U.S. Medicare beneficiaries were readmitted within 30 days after hospitalization for heart failure in 2022
Interpretation
Healthcare Operations Interpretation
From a healthcare operations standpoint, performance and process adoption look strong with 72% of hospitals using electronic health records, yet care continuity remains a clear challenge since 6.3% of Medicare patients were readmitted within 30 days after heart failure in 2022.
09 · Category
Industry Trends3 stats
01
The global market for cardiovascular devices was $41.5 billion in 2022
02
The global market for heart valve repair/replacement was $13.6 billion in 2022
03
The global anticoagulants market reached $34.2 billion in 2023
Interpretation
Industry Trends Interpretation
In industry trends, the pace of investment and demand is clear as the global cardiovascular devices market reached $41.5 billion in 2022 and the anticoagulants market climbed to $34.2 billion in 2023, showing sustained growth across major heart disease treatment categories.
report visual · Key figures
Heart Disease Risk Factors & Treatment Benefits at a Glance
Common risk factors remain widespread, while clinical trials show measurable relative risk reductions with cardiovascular therapies.
34.5%
Approximately 34.5% of U.S. adults have high total cholesterol (2015–2016 estimate, CDC)
18.2%
18.2% of U.S. adults aged 20+ had coronary artery disease in 2019–2020
11.5%
11.5% of U.S. adults (2017–2020) report current cigarette smoking
24%
In the HOPE-3 trial, rosuvastatin reduced the risk of cardiovascular events by 24% versus placebo
15%
In the CANTOS trial, canakinumab reduced recurrent major cardiovascular events by 15% compared with placebo
26%
In the DAPA-HF trial, dapagliflozin reduced the risk of worsening heart failure or cardiovascular death by 26% versus pl
source-verifiedcdc.gov · heart.org · nejm.org2019
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Aisha Okonkwo. (2026, February 13). Heart Disease Statistics. Gitnux. https://gitnux.org/heart-disease-statistics
MLA
Aisha Okonkwo. "Heart Disease Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/heart-disease-statistics.
Chicago
Aisha Okonkwo. 2026. "Heart Disease Statistics." Gitnux. https://gitnux.org/heart-disease-statistics.
Sources & references
43 datasets cited across this report · attribution is report-level
+25 additional datasets cited (not shown individually)